Table 1 Sensitivity and specificity of purified and electroeluted antigens with human sera
Purified and electroeluted antigens (kDa) | Sensitivity to active VL patients in % (n/N) | Sensitivity to 1-month treated VL patients in % (n/N) | Sensitivity to 6-month follow-up patients in % (n/N) | Specificity to other diseases in % (n’/N) | Specificity to healthy samples in % (n’/N) |
|---|---|---|---|---|---|
LAg | 100 (13/13) | 84.16 (11/13) | 0 (0/13) | 100 (13/13) | 100 (13/13) |
SLA | 100 (13/13) | 100 (13/13) | 7.69 (1/13) | 100 (13/13) | 100 (13/13) |
31 | 100 (23/23) | 60 (14/23) | 26.08 (6/23) | 39.1 (9/23) | 100 (23/23) |
34 | 100 (23/23) | 73.91 (17/23) | 13.04 (3/23) | 100 (23/23) | 100 (23/23) |
36 | 100 (23/23) | 69.56 (16/23) | 78.26 (18/23) | 40 (8/23) | 100 (23/23) |
45 | 100 (23/23) | 100 (23/23) | 60.86 (14/23) | 30.43 (7/23) | 60.86 (14/23) |
51 | 100 (23/23) | 91.30 (21/23) | 30.43 (7/23) | 100 (23/23) | 100 (23/23) |
63 | 100 (23/23) | 47.82 (11/23) | 4.34 (1/23) | 91.30 (21/23) | 95.65 (22/23) |
72 | 100 (23/23) | 39.1 (9/23) | 0 (0/23) | 65.21 (15/23) | 73.91 (17/23) |
91 | 100 (23/23) | 8.69 (2/23) | 0 (0/23) | 95.75 (22/23) | 91.30 (21/23) |
97 | 100 (23/23) | 78.23 (18/23) | 86.95 (20/23) | 95.75 (22/23) | 100 (23/23) |